Price T Rowe Associates Inc Tango Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 40,669 shares of TNGX stock, worth $332,265. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,669
Previous 38,401
5.91%
Holding current value
$332,265
Previous $197,000
74.11%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TNGX
# of Institutions
147Shares Held
130MCall Options Held
170KPut Options Held
17.6K-
Trv Gp Iv, LLC Boston, MA13.9MShares$113 Million100.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA10.8MShares$87.9 Million0.39% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$86.9 Million6.71% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA8.54MShares$69.7 Million8.04% of portfolio
-
Woodline Partners LP San Francisco, CA6.03MShares$49.3 Million0.26% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $720M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...